Buy or sell MacuLogix stock pre IPO via an EquityZen fund

EquityZen is a marketplace for shares of proven pre IPO tech companies

MacuLogix Stock

Detecting and tracking age-related macular degeneration

About MacuLogix Stock

MacuLogix aims to detect early and track age-related macular degeneration (AMD). MacuLogix’ AdaptDx™ has received FDA 510(k) clearance for measurement of dark adaptation function and patient testing has been completed to support validation as a diagnostic for AMD. 

Funding History

July 2012$2.9M
March 2013$3.6M
June 2014$3.6M
October 2015$5.0M
July 2018$10.0M
March 2019$38.7M

Management

Co-founder and Chief Scientific Officer

Gregory R. Jackson

CEO

Bill McPhee

Other Companies

EquityZen does not have an affiliation with, formal relationship with, or endorsement from MacuLogix or any companies feature above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 100K+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

LogoLogo